May 2018 - Evolution Biotechnologies
archive,date,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Evolution Biotechnologies (, the UK and US-based company extending the use of biological control into medically important areas, today announced the publication of an invited paper written by Dr. David Harper, its Chief Executive Officer, as part of a special edition of the journal “Viruses”. The special edition is edited by Dr. Harald Brüssow and is focussed on “Hurdles for Phage Therapy (PT) to Become a Reality”. The paper, entitled “Criteria for Selecting Suitable Infectious Diseases for Phage Therapy” (Viruses 2018, 10(4), 177; can be viewed at About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027) has been established to extend...